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Postmenopausal Hormone Therapy and Atherosclerosis — 
Time Is of the Essence
John F. Keaney, Jr., M.D., and Caren G. Solomon, M.D.
Multiple prospective cohort studies in the 1980s 
indicated that hormone therapy was associated 
with a nearly 50% lower risk of coronary heart 
disease in postmenopausal women,1 which 
prompted speculation that such therapy could be 
used to prevent coronary events. However, sub-
sequent large-scale randomized trials that evalu-
ated the effect of postmenopausal hormone 
therapy failed to support the presence of a car-
diovascular benefit. Among women with estab-
lished coronary heart disease, combined estro-
gen–progestin therapy resulted in an increased 
risk of coronary heart disease events at 1 year 
and had no significant effects on the risk of 
coronary heart disease events in longer-term 
follow-up.2 In the Women’s Health Initiative, 
which involved mostly primary prevention, estro-
gen and progestin therapy resulted in signifi-
cantly increased risks of coronary heart disease 
events and stroke,3,4 and estrogen alone pro-
duced an increased risk for stroke and no signifi-
cant reduction in coronary heart disease events.5
Since, as compared with the randomized tri-
als, the earlier cohort studies involved younger 
women who generally started hormone therapy 
soon after menopause, one proposed explana-
tion to reconcile these data has been that hor-
mone therapy is effective only when initiated in 
early stages of atherosclerosis — that is, around 
the time of menopause. In this issue of the Jour-
nal, Hodis et al.6 provide a test of this hypothesis 
in the Early versus Late Intervention Trial with 
Estradiol (ELITE). In this single-center trial, 643 
postmenopausal women free from cardiovascu-
lar disease were stratified according to time 
since menopause (<6 years [early] vs. ≥10 years 
[late]) and were randomly assigned to receive ei-
ther estrogen as 17β-estradiol (plus micronized 
progesterone vaginal gel for women with a 
uterus) or placebo (plus placebo vaginal gel for 
women with a uterus) over a median of 5 years. 
The primary outcome was atherosclerosis pro-
gression, measured by means of ultrasonogra-
phy as carotid-artery intima–media thickness 
(CIMT). As compared with placebo, estrogen 
treatment resulted in a significantly lower rate 
of atherosclerosis progression among early post-
menopausal women but not among late post-
menopausal women. The results were similar 
regardless of whether the women also received 
progesterone. There was no significant difference 
between estradiol and placebo in either the early 
or the late postmenopause stratum with regard 
to a secondary outcome, measurement of athero-
sclerosis by cardiac computerized tomography 
(CT) at the end of the study; however, this assess-
ment was performed in only a subset of women, 
and no baseline measures were available.
The ELITE results support the hypothesis that 
the beneficial effects of exogenous estrogen on 
the progression of atherosclerosis are dependent 
on the timing of the initiation of therapy and are 
limited to women who start therapy within sev-
eral years of menopause. These data are of keen 
biologic interest, because they suggest that fa-
vorable responses of receptors in the vasculature 
to estrogen may be lost with lack of exposure to 
estrogen. This contention is consistent with ani-
mal studies that have established the estrogen 
receptor as being responsible for salutary vascu-
lar and anti-inflammatory effects of estrogen 
and have shown a loss of this response with 
older age or prolonged estrogen deprivation.7,8
Despite the favorable effect of estrogen on 
atherosclerosis in early postmenopausal women 
in the ELITE trial, the relevance of these results 
to clinical coronary heart disease events remains 
questionable. The trial assessed only surrogate 
measures of coronary heart disease and was not 
designed or powered to assess clinical events. 
The occurrence of myocardial infarction and 
stroke involves not only atherosclerotic plaque 
formation but also plaque rupture and thrombo-
sis. Any changes in these latter two phenomena 
would not be captured by the CIMT measure-
ments in ELITE — a point of particular interest, 
given that postmenopausal hormone therapy may 
promote thrombosis and inflammation. Also, not 
all interventions that improve CIMT progression 
translate into lower rates of coronary events.9
A final caution is that the available clinical 
data in support of the timing hypothesis are 
suggestive but inconsistent. Early reports of ef-
fects of postmenopausal hormone therapy on the 
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risk of coronary heart disease in the Women’s 
Health Initiative noted no significant inter-
actions according to age or time since meno-
pause.4,5 Whereas some subsequent analyses of 
the Women’s Health Initiative data have indicated 
differential effects of postmenopausal hormone 
therapy according to age or time since meno-
pause,10 these post hoc subgroup examinations 
are most appropriately viewed as hypothesis-
generating.
In light of the available data from random-
ized trials, guidelines from various professional 
organizations11,12 currently caution against using 
postmenopausal hormone therapy for the purpose 
of preventing cardiovascular events. Although 
the ELITE trial results support the hypothesis 
that postmenopausal hormone therapy may have 
more favorable effects on atherosclerosis when 
initiated soon after menopause, extrapolation of 
these results to clinical events would be prema-
ture, and the present guidance remains prudent.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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